User login
Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).
Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.
Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.
Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w
Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).
Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.
Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.
Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w
Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).
Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.
Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.
Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w